(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.26%.
Cogent Biosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast COGT's revenue for 2025 to be $1,160,174,908, with the lowest COGT revenue forecast at $1,160,174,908, and the highest COGT revenue forecast at $1,160,174,908. On average, 5 Wall Street analysts forecast COGT's revenue for 2026 to be $6,501,138,601, with the lowest COGT revenue forecast at $270,342,644, and the highest COGT revenue forecast at $19,832,423,896.
In 2027, COGT is forecast to generate $28,563,506,230 in revenue, with the lowest revenue forecast at $7,645,114,841 and the highest revenue forecast at $66,119,024,698.